Semaglutide & Tirzepatide

Fat LossApproved incretin class overviewEstablished

Also known as: GLP-1 vs dual GIP/GLP-1 comparison entry

Semaglutide & Tirzepatide (also called GLP-1 vs dual GIP/GLP-1 comparison entry) is a research peptide in the GLP-1 Agonist class. This entry compares two approved incretin agents that differ in receptor coverage. Semaglutide is a mono-agonist at the GLP-1 receptor, acylated for weekly dosing, producing glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying and centrally mediated appetite reduction.

Calculate Dose

For research use only.

Key Facts

CAS
—
Molecular Weight (MW)
—
Half-life
See individual products (~5–7 days)
FDA status
Not Approved
Evidence level
Insufficient Evidence
Human dose established
No
Administration Route
Not established in humans
Frequency
Not established in humans
Last updated
Nov 7, 2026
Reviewed
Nov 7, 2026
Targets
GLP-1 receptorGIP receptor (tirzepatide)

Research summary

Library comparison card for two FDA-approved weekly incretins: semaglutide (GLP-1) and tirzepatide (GIP/GLP-1). Each is approved on its own; the combination is not approved, and both labels say use with another GLP-1 receptor agonist is not recommended.

Research evidence

  • Regulatory review (FDA label)None in reviewed sources
  • Controlled human trialsNone in reviewed sources
  • Early or uncontrolled human studiesNone in reviewed sources
  • Lab & animal studiesNone in reviewed sources
How it works

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

Peptide Library's Semaglutide & Tirzepatide profile summarises 3 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.

Semaglutide & Tirzepatide dosage: no established human dose

Semaglutide and tirzepatide taken together have no established human dosage. No published or registered study has given the two together as one treatment. Each is FDA-approved on its own, with its own label: Wegovy (semaglutide) is escalated to a 2.4 mg once-weekly maintenance dose for weight reduction, and Zepbound (tirzepatide) starts at 2.5 mg once weekly and is escalated to 5, 10 or 15 mg once weekly. The trials that include both drugs compare them with each other rather than combine them.

Insufficient Evidence

No established human dosage.

Human clinical evidence: None identified.

Preclinical research: This entry pairs two approved incretin drugs: semaglutide, a GLP-1 receptor agonist, and tirzepatide, a dual GIP and GLP-1 receptor agonist. Both act on the GLP-1 receptor. PubMed and ClinicalTrials.gov list many studies that include both drugs, but they compare them, enrol people taking either one, or follow people who switched from one to the other. None gives the two together as a combined treatment, so there is no dose, safety or outcome data for the combination.

Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.

Dosage evidence summary for Semaglutide & Tirzepatide
Human dosing establishedNo
RouteNot established for the combination
Evidence levelInsufficient Evidence
Last reviewed2026-11-07

Preclinical and analog research

Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.

Research-reported dosing for Semaglutide & Tirzepatide, one row per studied regimen
Study / contextPopulationDoseRouteFrequencyDurationOutcome studiedSource
Component (analog evidence) — semaglutide: FDA label, Wegovy, weight reduction in adultsFDA-approved label · FDA prescribing information for one component aloneStudied an analog, not Semaglutide & Tirzepatide itselfAdults with obesity, or overweight with a weight-related condition2.4 mg maintenance (1.7 mg alternative); maximum 7.2 mg, semaglutide aloneSubcutaneousOnce weeklyEscalated over 16 weeks, then continuousChronic weight managementWEGOVY (semaglutide) injection — FDA prescribing information, DailyMed
Component (analog evidence) — tirzepatide: FDA label, Zepbound, weight reductionFDA-approved label · FDA prescribing information for one component aloneStudied an analog, not Semaglutide & Tirzepatide itselfAdults with obesity, or overweight with at least one weight-related comorbid condition5 mg, 10 mg or 15 mg maintenance; 2.5 mg starting dose, tirzepatide aloneSubcutaneousOnce weeklyLong termReduction and maintenance of body weightZEPBOUND (tirzepatide) injection — FDA prescribing information, DailyMed
Component (analog evidence) — SURPASS-2: tirzepatide compared with semaglutide, not combined (NCT03987919)Clinical trial · Phase 3 open-label randomised head-to-head trial of the components given separatelyStudied an analog, not Semaglutide & Tirzepatide itselfAdults with type 2 diabetes (n=1,879)Tirzepatide 5 mg, 10 mg or 15 mg, or semaglutide 1 mg, each in a separate groupSubcutaneousOnce weekly40 weeksGlycated haemoglobin change of -2.01, -2.24 and -2.30 points with tirzepatide 5, 10 and 15 mg against -1.86 with semaglutide; no group received both drugsFrías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021.

Where sources disagree

  • Each drug's approved dose comes from its own label, tested on its own. A dose of semaglutide or tirzepatide taken alongside the other is not a dose that was studied. See the Semaglutide and Tirzepatide profiles for each drug's labelled regimens.
  • Both labels say the opposite of combining them. The Wegovy label says use with any other GLP-1 receptor agonist is not recommended, and the Zepbound label says coadministration with any GLP-1 receptor agonist is not recommended. Tirzepatide also acts on the GLP-1 receptor.
  • One UK physiology study, not yet recruiting (NCT07483801), plans one-off infusions of semaglutide and tirzepatide into an artery or vein to measure effects on blood vessels. It is not a treatment regimen and has no results.
  • This entry is not sold as a combined vial in the shop listings checked, so there is no blend to reconstitute.

Handling & administration

Injection Sites
AbdomenThighUpper arm
Timing Notes
Each drug is injected once weekly on the same day each week, as its own label describes. The Wegovy and Zepbound labels say use with another GLP-1 receptor agonist is not recommended.
Expected Onset
1–4 weeks (appetite), 8–12+ weeks (weight)

Sequence & molecular data

Sequence and molecular data for Semaglutide & Tirzepatide
Half-lifeSee individual products (~5–7 days)
AppearancePrefilled pen (Rx) or research vials (where applicable)
FormulationPrefilled Pen

Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.

Science

Mechanism of Action

This entry compares two approved incretin agents that differ in receptor coverage. Semaglutide is a mono-agonist at the GLP-1 receptor, acylated for weekly dosing, producing glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying and centrally mediated appetite reduction. Tirzepatide activates both the GIP and GLP-1 receptors from a single peptide, with agonism weighted toward GIPR and biased signalling at GLP-1R that limits receptor desensitisation. The added GIP activity is the pharmacological difference, and head-to-head trial data in obesity has shown greater mean weight reduction with tirzepatide. Both are prescription medicines with class-typical gastrointestinal effects.

Origin

Two separate approved peptide drugs.

Targets

GLP-1 receptorGIP receptor (tirzepatide)

Regulatory & research status

Semaglutide & Tirzepatide is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

Regulatory and research status for Semaglutide & Tirzepatide
FDA statusNot Approved
AvailabilityPrescription-Only
WADA (sport)Permitted
Library classificationFDA-Approved

How FDA approval, compounding and research-only status differ

Benefits

Class comparison for education

Semaglutide & Tirzepatide side effects

Semaglutide & Tirzepatide has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.

Side Effects

  • Shared GI class effects

Contraindications

  • Titrate slowly to manage GI effects; follow Rx guidance

Storage & stability

This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.

Semaglutide & Tirzepatide: frequently asked questions

What is Semaglutide & Tirzepatide?

Library comparison card for two FDA-approved weekly incretins: semaglutide (GLP-1) and tirzepatide (GIP/GLP-1). Not a single combination drug.

How does Semaglutide & Tirzepatide work?

This entry compares two approved incretin agents that differ in receptor coverage. Semaglutide is a mono-agonist at the GLP-1 receptor, acylated for weekly dosing, producing glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying and centrally mediated appetite reduction.

Is Semaglutide & Tirzepatide FDA approved?

Yes. Semaglutide & Tirzepatide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.

What is the half-life of Semaglutide & Tirzepatide?

Reported half-life for Semaglutide & Tirzepatide is See individual products (~5–7 days). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

Is Semaglutide & Tirzepatide banned in sport?

Semaglutide & Tirzepatide is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.

What peptides are similar to Semaglutide & Tirzepatide?

Compounds most often compared with Semaglutide & Tirzepatide include Amycretin, CagriSema, Cotadutide and Dulaglutide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

References

Related research, comparisons & guides

Related peptides

Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 3

This Semaglutide & Tirzepatide profile is compiled from published literature (3 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error

Track Semaglutide & Tirzepatide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →